Efficacy of immunoglobulin replacement therapy and azithromycin in severe asthma with antibody deficiency

Background: Although antibody deficiency (AD) is a well-known cause of recurrent respiratory infections, there are few data on its impact in adults with asthma. The objective of the present study was to assess outcomes in adults with severe asthma and AD after treatment with either azithromycin or subcutaneous immunoglobulins (SCIg). Methods: We performed a 5-year, prospective, observational, two-centre study of adults with severe asthma and AD in France. Bronchiectasis was ruled out by high-resolution computed tomography. Patients were treated for one year with either azithromycin (250 mg every other day) or SCIg (0.4-0.6 g/kg/months, weekly). All patients were evaluated for exacerbations, asthma control and lung function at baseline and then one year after treatment initiation. Results: Thirty-nine patients with severe asthma were included in the study: 14 had been treated with azithromycin and 25 had been treated with SCIg. Before the initiation of treatment for AD, all patients had an Asthma Control Questionnaire (ACQ-7) score > 1.5 (mean +/- SD: 2.71 +/- 0.53) despite treatment at GINA step 4 or 5, and had a high exacerbation rate requiring oral corticosteroids and/or rescue antibiotics (similar to 7.2 +/- 2.1/patient/year). One year after treatment initiation, we observed a significantly higher FEV1 (mean: 0.18 +/- 0.22 L) and ACQ-7 score (1.26 +/- 0.68), and a significantly lower exacerbation rate (1.63 +/- 1.24/patient/year). Conclusions: Treatment of AD dramatically improved asthma outcomes - suggesting that adults with severe asthma and recurrent respiratory infections should be screened and (if appropriate) treated for AD. Copyright (C) 2019, Japanese Society of Allergology. Production and hosting by Elsevier B.V.